Biomarkers for the lung cancer diagnosis and their advances in proteomics.

摘要: Over a last decade, intense interest has been focused on biomarker discovery and their clinical uses. This is accelerated by the completion of human genome project progress techniques in proteomics. Especially, cancer eminent this field due to its anticipated critical role early diagnosis, therapy guidance, prognosis monitoring cancers. Among cancers, lung cancer, one top three major showing highest mortality because failure diagnosis. Numerous potential DNA biomarkers such as hypermethylations promoters mutations K-ras, p53, protein biomarkers; carcinoembryonic antigen (CEA), CYFRA21-1, plasma kallikrein B1 (KLKB1), Neuron-specific enolase, etc. have discovered biomarkers. Despite extensive studies thus far, few are turned out be useful clinic. Even those used clinic do not show enough sensitivity, specificity reproducibility for general use. review describes what for, various types at present predicted future advance with proteomics technology.